Evidence map›Paper›PMID 30517737›Full record

ReviewJournal of the National Cancer Institute2018

Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide.

Sebastian Walpole, Antonia L Pritchard, Colleen M Cebulla, Robert Pilarski, Meredith Stautberg, Frederick H Davidorf, Arnaud de la Fouchardière, Odile Cabaret, Lisa Golmard, Dominique Stoppa-Lyonnet and 67 more

Abstract readReview
In one paragraph

Review in Journal of the National Cancer Institute, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
145citing papers in PubMed, 3 pooled it
8.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

145 citing papers in PubMed, 3 syntheses or guidelines pooled it, 232 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

85 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

77 authors at 20 institutions in 15 countries.

Sebastian WalpoleQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Antonia L PritchardQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Colleen M CebullaDepartment of Ophthalmology and Visual Science, The Ohio State University, Columbus, OH.
Robert PilarskiDivision of Human Genetics, Department of Internal Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH.
Meredith StautbergDivision of Human Genetics, Department of Internal Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH.
Frederick H DavidorfDepartment of Ophthalmology and Visual Science, The Ohio State University, Columbus, OH.
Arnaud de la FouchardièreDépartement of Biopathology, Centre Leon Bérard, Lyon, France.
Odile CabaretDépartement de Biopathologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Lisa GolmardDépartement De Biologie Des Tumeurs, Institut Curie, Paris, France.
Dominique Stoppa-LyonnetDépartement De Biologie Des Tumeurs, Institut Curie, Paris, France.
Erin GarfieldDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL.
Ching-Ni NjauwDepartment of Dermatology, Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA.
Mitchell CheungCancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA.
Joni A TurunenFolkhälsan Institute of Genetics, Helsinki, Finland.
Pauliina RepoFolkhälsan Institute of Genetics, Helsinki, Finland.
Reetta-Stiina JärvinenFolkhälsan Institute of Genetics, Helsinki, Finland.
Remco van DoornDepartment of Dermatology, LUMC, Leiden, The Netherlands.
Martine J JagerDepartment of Ophthalmology, LUMC, Leiden, The Netherlands.
Gregorius P M LuytenDepartment of Ophthalmology, LUMC, Leiden, The Netherlands.
Marina MarinkovicDepartment of Ophthalmology, LUMC, Leiden, The Netherlands.
Cindy ChauDepartment of Ophthalmology, LUMC, Leiden, The Netherlands.
Miriam PotronyDermatology Department, Melanoma Unit, Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Veronica HöiomDepartment of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Hildur HelgadottirDepartment of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Lorenza PastorinoDepartment of Internal Medicine and Medical Specialties and Genetics of Rare Cancers, University of Genoa, Ospedale Policlinico San Martino, Genoa, Italy.
William BrunoDepartment of Internal Medicine and Medical Specialties and Genetics of Rare Cancers, University of Genoa, Ospedale Policlinico San Martino, Genoa, Italy.
Virginia AndreottiDepartment of Internal Medicine and Medical Specialties and Genetics of Rare Cancers, University of Genoa, Ospedale Policlinico San Martino, Genoa, Italy.
Bruna DalmassoDepartment of Internal Medicine and Medical Specialties and Genetics of Rare Cancers, University of Genoa, Ospedale Policlinico San Martino, Genoa, Italy.
Giulia CiccareseDepartment of Internal Medicine and Medical Specialties and Genetics of Rare Cancers, University of Genoa, Ospedale Policlinico San Martino, Genoa, Italy.
Paola QueiroloMedical Oncology Unit, Ospedale Policlinico San Martino, Genoa, Italy.
Luca MastracciDepartment of Surgical and Diagnostic Sciences, Pathology Unit, University of Genoa and Ospedale Policlinico San Martino, Genoa, Italy.
Karin WadtDepartment of Clinical Genetics, University Hospital of Copenhagen, Copenhagen, Denmark.
Jens Folke KiilgaardDepartment of Ophthalmology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Michael R SpeicherInstitute of Human Genetics, Diagnostic and Research Center for Molecular Biomedicine, Medical University of Graz, Graz, Austria.
Natasha van PoppelenDepartment of Ophthalmology.
Emine KilicDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, the Netherlands.
Rana'a T Al-JamalDepartment of Ophthalmology, Ocular Oncology Service, Helsinki University Central Hospital, Helsinki, Finland.
Irma DianzaniDepartment of Health Sciences, Università del Piemonte Orientale, Novara, Italy.
Marta BettiDepartment of Health Sciences, Università del Piemonte Orientale, Novara, Italy.
Carsten BergmannBioscientia Center for Human Genetics, Ingelheim, Germany.
Sandro SantagataDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Sonika DahiyaDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO.
Saleem TaibjeeDepartment of Dermatology, Dorset County Hospital NHS Foundation Trust, Dorchester, UK.
Jo BurkeTasmanian Clinical Genetics Service, Royal Hobart Hospital, TAS, Australia.
Nicola PoplawskiAdult Genetics Unit, Medicine Directorate, Royal Adelaide Hospital, Adelaide, SA, Australia.
Sally J O'SheaDermatology Department, Mater Private Hospital Cork, Citygate, Mahon, Cork, Ireland.
Julia Newton-BishopYorkshire Regional Genetics Service, Chapel Allerton Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Julian AdlardYorkshire Regional Genetics Service, Chapel Allerton Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
David J AdamsExperimental Cancer Genetics, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, UK.
Anne-Marie LaneDepartment of Ophthalmology, Ocular Melanoma Center and Retina Service, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA.
Ivana KimDepartment of Ophthalmology, Ocular Melanoma Center and Retina Service, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA.
Sonja KlebeDepartment of Anatomical Pathology, Flinders University and SA Pathology at Flinders Medical Centre, Adelaide, SA, Australia.
Hilary RacherImpact Genetics, Bowmanville, Ontario, Canada.
J William HarbourBascom Palmer Eye Institute, Sylvester Comprehensive Cancer Center and Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL.
Michael L NickersonLaboratory of Translational Genomics, National Cancer Institute, Bethesda, MD.
Rajmohan MuraliDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
Jane M PalmerQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Madeleine HowlieQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Judith SymmonsQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Hayley HamiltonQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Sunil WarrierQueensland Ocular Oncology Service, The Terrace Eye Centre, Brisbane, QLD, Australia.
William GlassonQueensland Ocular Oncology Service, The Terrace Eye Centre, Brisbane, QLD, Australia.
Peter JohanssonQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Carla Daniela Robles-EspinozaExperimental Cancer Genetics, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, UK.
Raul OssioLaboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Juriquilla, Santiago de Querétaro, Mexico.
Annelies de KleinDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, the Netherlands.
Susana PuigCentro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain.
Paola GhiorzoDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL.
Maartje NielsenDepartment of Clinical Genetics, LUMC, Leiden, The Netherlands.
Tero T KiveläDepartment of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Hensin TsaoDepartment of Dermatology, Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA.
Joseph R TestaCancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA.
Pedram GeramiDepartment of Internal Medicine and Medical Specialties and Genetics of Rare Cancers, University of Genoa, Ospedale Policlinico San Martino, Genoa, Italy.
Marc-Henri SternDépartement De Biologie Des Tumeurs, Institut Curie, Paris, France.
Brigitte Bressac-de PailleretsDépartement de Biopathologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Mohamed H Abdel-RahmanDepartment of Ophthalmology and Visual Science, The Ohio State University, Columbus, OH.
Nicholas K HaywardQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
QIMR Berghofer Medical Research Institute · AULeiden University Medical Center · NLThe Ohio State University · USUniversity of Genoa · ITErasmus MC · NLNorthwestern University · USOspedale Policlinico San Martino · ITUniversity of Helsinki · FICity Eye Centre · AUFox Chase Cancer Center · USHelsinki University Hospital · FIInstitut Curie · FRKarolinska Institutet · SEMassachusetts General Hospital · USUniversidad Nacional Autónoma de México · MXUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITBrigham and Women's Hospital · USCentre Léon Bérard · FRCentro de Investigación Biomédica en Red · ESChapel Allerton Hospital · GB

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
University of Iowa Clinical and Translational Science Program (TL1)UL1RR025755 · NCRR · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA D · 2008 to 2011
$26.3M
Genetic Epidermiology of MelanomaR01CA083115 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BISHOP, DAVID TIMOTHY, ELDER, DAVID ERIC · 2001 to 2017
$13.0M
Pathogenesis of Malignant Mesothelioma by the Human Polycomb Complex BAP1-ASXLR01CA175691 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI RAUSCHER III, FRANK JOSEPH, TESTA, JOSEPH R. · 2014 to 2018
$2.7M
Molecular Risk Assessment in Hereditary MelanomaK24CA149202 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI TSAO, HENSIN · 2010 to 2019
$1.9M
Genetic polymorphisms in retinal detachment with proliferative vitreoretinopathyK08EY022672 · NEI · OHIO STATE UNIVERSITY · PI CEBULLA, COLLEEN MARIE · 2012 to 2016
$1.1M
Hereditary cancer predisposition syndromes and uveal melanomaR21CA191943 · NCI · OHIO STATE UNIVERSITY · PI ABDEL-RAHMAN, MOHAMED H. · 2015 to 2016
$368k
Cancer Research UK 10589Cancer Research UK 19167NCI NIH HHS K24 CA149202NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA083115NCI NIH HHS R01 CA175691NCI NIH HHS R21 CA191943NCRR NIH HHS UL1 RR025755NEI NIH HHS K08 EY022672Wellcome Trust 204562/Z/16/Z
6 · The paper itself

Abstract

Background: The BRCA1-associated protein-1 (BAP1) tumor predisposition syndrome (BAP1-TPDS) is a hereditary tumor syndrome caused by germline pathogenic variants in BAP1 encoding a tumor suppressor associated with uveal melanoma, mesothelioma, cutaneous melanoma, renal cell carcinoma, and cutaneous BAP1-inactivated melanocytic tumors. However, the full spectrum of tumors associated with the syndrome is yet to be determined. Improved understanding of the BAP1-TPDS is crucial for appropriate clinical management of BAP1 germline variant carriers and their families, including genetic counseling and surveillance for new tumors. Methods: We collated germline variant status, tumor diagnoses, and information on BAP1 immunohistochemistry or loss of somatic heterozygosity on 106 published and 75 unpublished BAP1 germline variant-positive families worldwide to better characterize the genotypes and phenotypes associated with the BAP1-TPDS. Tumor spectrum and ages of onset were compared between missense and null variants. All statistical tests were two-sided. Results: The 181 families carried 140 unique BAP1 germline variants. The collated data confirmed the core tumor spectrum associated with the BAP1-TPDS and showed that some families carrying missense variants can exhibit this phenotype. A variety of noncore BAP1-TPDS -associated tumors were found in families of variant carriers. Median ages of onset of core tumor types were lower in null than missense variant carriers for all tumors combined (P < .001), mesothelioma (P < .001), cutaneous melanoma (P < .001), and nonmelanoma skin cancer (P < .001). Conclusions: This analysis substantially increases the number of pathogenic BAP1 germline variants and refines the phenotype. It highlights the need for a curated registry of germline variant carriers for proper assessment of the clinical phenotype of the BAP1-TPDS and pathogenicity of new variants, thus guiding management of patients and informing areas requiring further research.

Indexed as

Genetic Association StudiesGenetic Predisposition to DiseaseGerm-Line MutationAge of OnsetAllelesFemaleGene FrequencyGenotypeHumansMaleNeoplastic Syndromes, HereditaryPhenotypeRisk AssessmentTumor Suppressor ProteinsUbiquitin ThiolesteraseBAP1 protein, humanTumor Suppressor ProteinsUbiquitin Thiolesterase

Identifiers

PMID30517737
PMCPMC6292796
OpenAlexW2903799300

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.